Advance of Mechanisms and Clinical Applications about Rapamycin for Treating Immune Mediated Hemocytopenia--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1836-1840, 2018.
Artigo
em Chinês
| WPRIM
| ID: wpr-774376
ABSTRACT
Immune-mediated hemocytopenia is a common cytopenic diseases without bone marrow hematopoietic abnormalities, the patient's quality of life is significantly reduced when first-line treatments are ineffective. Rapamycin, possesses a clear mechanism of targeting mTOR protein, can upregulate regulatory T cells and induces apoptosis of specific cells, by regulating the lymphocyte subsets, so as to treat various types of immune-mediated hemocytopenia with a certain therapeutic effect. In this reviews, the action mechanism and clinical application of rapamycin in immune thrombocytopenia(ITP), autoimmune hemolytic anemia(AIHA), acquired aplastic anemia and autoimmune lymphoproliferative syndrome(ALPS) etc. are summarized.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Qualidade de Vida
/
Linfócitos T Reguladores
/
Sirolimo
/
Usos Terapêuticos
/
Serina-Treonina Quinases TOR
/
Anemia Aplástica
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS